Silexion Therapeutics Corp SLXN
0.15 USD 0.00 (+0.97%)
At closeNov 9, 2026, 5:04 AM EST
0.14 0.00 -1.52%
Pre-market · Nov 9, 5:04 AM ET
0.1441 Day range 0.152
0.14 52-week range 32.38
- YTD
- -99.24%
- 1 year
- -99.48%
Financial health
Altman Z-Score
-31.26 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -0.2×
FY 2020 5y median -0.2× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 1.0×
FY 2020 5y median -0.1× FY 2025
P/FCF -0.2×
FY 2020 5y median -0.4× FY 2025
EV/EBITDA 0.2×
FY 2020 5y median -0.3× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -424.2%
FY 2020 5y median -231.5% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -457.6%
FY 2020 5y median 30.1% FY 2025
ROIC 250.7%
FY 2020 5y median -49.2% FY 2025
ROA -165.1%
FY 2020 5y median -94.0% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income 192.5%
FY 2020 FY 2025
EPS (diluted) 97.7%
FY 2020 FY 2025
Free Cash Flow -28.6%
FY 2020 FY 2025
Financial Health
Current Ratio 2.4×
FY 2020 5y median 2.3× FY 2025
Quick Ratio 2.4×
FY 2020 5y median 2.3× FY 2025
Debt / Equity 0.2×
FY 2020 5y median -0.0× FY 2025
Net Debt / EBITDA 0.5×
FY 2020 5y median 0.5× FY 2025
Interest Coverage 895×
FY 2020 5y median -45.4× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31